Pictet Asset Management
STOK icon

Pictet Asset Management’s Stoke Therapeutics STOK Stock Holding History

Pictet Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Hold
7,581
– – ﹤0.01% 1874
2026
Q1 		$247K Buy
+7,581
New +$249K ﹤0.01% 1826

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pictet Asset Management's STOK Position: Q2 2026 in Review

Pictet Asset Management held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 7,581 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

Pictet Asset Management first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Pictet Asset Management held 7,581 shares of Stoke Therapeutics worth $248K as of Q2 2026.
  • Pictet Asset Management left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1874 holding.
  • Pictet Asset Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.